二肽基肽酶4抑制剂对骨代谢影响的研究进展  

Research progress of dipeptidyl peptidase 4 inhibitors on bone metabolism

作　　者：王玉莹 刘蕴玲[1] WANG Yuying;LIU Yunling(Department of Gerontology,The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital,Jinan 250014,China)

机构地区：[1]山东第一医科大学第一附属医院(山东省千佛山医院)老年医学科,济南250014

出　　处：《中国糖尿病杂志》2022年第2期144-146,共3页Chinese Journal of Diabetes

摘　　要：DM患者患骨质疏松症的患病风险较高。二肽基肽酶4(DPP-4)广泛表达于全身组织器官。DPP-4抑制剂通过诱导间充质干细胞分化、减少AGEs聚集、增加IGF-1自分泌、抑制炎症因子表达、延长GLP-1及葡萄糖依赖性促胰岛素分泌多肽半衰期、促进APN分泌、改善维生素D水平、降低硬骨素水平等途径,对骨代谢产生一定影响。本文对DPP-4抑制剂对骨代谢的研究进展进行综述,旨在为临床治疗DM合并骨质疏松症提供依据。Patients with diabetes mellitus(DM)have an increased risk of osteoporosis.Dipeptidyl peptidase 4(DPP-4)is widely expressed in various tissues and organs..DPP-4 inhibitor can induce the differentiation of mesenchymal stem cells,reduce the accumulation of advanced glycation end(AGE)products,increase the autocrine of IGF-1,inhibit the expression of inflammatory factors,prolong the half-life of glucagon like peptide 1 and glucose dependent insulin-stimulating peptide,promote the secretion of APN,improve the level of Vitamin D,and reduce the level of osteocalcin.This article reviews the research progress of DPP-4 inhibitors on bone metabolism in order to provide basis for clinical treatment of DM with osteoporosis.

关 键 词：二肽基肽酶4抑制剂 骨代谢 

分 类 号：R580[医药卫生—内分泌] R587.1[医药卫生—内科学]